Meet the third cohort who are taking part in FLIER, our cross-sector leadership programme:
Dr Rubina Ahmed, Director of Research, Policy and Services, Blood Cancer UK
(Job title at the start of the programme: Dr Rubina Ahmed, Associate Director for Systems Engagement, Stroke Association)
Dr Rubina Ahmed holds a PhD in Immunology and an MSc in Management. She has a background in scientific research funding, organisational strategy, and management, and has built a career across the public and medical research charity sectors.
She joined Blood Cancer UK in July 2023 as Director of Research, Policy and Services. Here she is part of the Executive Leadership team accountable for the “mission-facing” directorate responsible for delivering programmes that benefit people affected by blood cancer. This includes overseeing the research funding programmes, clinical trials programmes, beneficiary services such as the helpline, health information, healthcare professional engagement, policy and advocacy, and involvement and volunteering.
Previously she was the Associate Director for Systems Engagement at the Stroke Association, where she was responsible for a wide portfolio of activities, including research funding, policy, public affairs and campaigns, health inequalities, international engagement, and broader objectives around working in partnership with system decision-makers at the local and national level. Rubina’s team worked collaboratively with NHS England to support the delivery of the stroke ambitions in the NHS England Long Term Plan. She was a member of the NHS England Stroke Delivery Programme Board and Board Member of the Stroke Alliance for Europe.
Other organisations she has worked for include the Wellcome Trust, NC3Rs and Cancer Research UK, working across a range of areas from fundamental and translational research through to clinical trials regulation and delivery. Alongside her work at Blood Cancer UK, she is an experienced charity Trustee and is currently a Council Member of the British Science Association, and a Trustee for Pro Bono Economics.
Professor Alex Casson, Professor of Biomedical Engineering, University of Manchester
(Job title at the start of the programme: Dr Alex Casson, Reader (Associate Professor), Department of Electrical and Electronic Engineering, University of Manchester)
Alex Casson is a Professor of Biomedical Engineering at the University of Manchester. He is a specialist in non-invasive bioelectronic interfaces: the design and application of wearable sensors, and skin-conformal flexible sensors, for human body monitoring and data analysis from highly artefact-prone naturalistic situations. This work is highly multidisciplinary, spanning ultra-low power sensing, signal processing and machine learning in power-constrained rich environments, and real-time data analysis towards closed loop systems.
Professor Casson’s ultra-low power sensors work is mainly for health and wellness applications, with a strong background in brain interfacing (EEG and transcranial current stimulation) and heart monitoring. Applications focus on both mental health situations, including chronic pain, sleep disorders, and autism, and physical health/rehabilitation applications including diabetic foot ulceration.
Professor Casson has cross-disciplinary appointments to support this work. He is a Professor in the School of Engineering at the University of Manchester; Visiting Reader (2022–2024) in the School of Medicine at the University of Leeds; and Honorary Reader (2022–2024) in the Medical Physics Department at Northern Care Alliance NHS Foundation Trust.
He is a Future Leader in Innovation, Enterprise and Research (FLIER) for the Academy of Medical Sciences (2022–2024), Bioelectronics technology platform lead for the Henry Royce Institute, and previously a Fellow of the Alan Turing Institute (2021–2023). Professor Casson is currently a Senior Member of the IEEE and Fellow of the Higher Education Academy. He is a past chair of the IET Healthcare Technologies Network, and the Biomedical Engineering joint steering group.
Professor Joan Condell, Professor of Intelligent Technologies, Ulster University
(Job title at the start of the programme: Professor Joan Condell, School of Computing, Engineering and Intelligent Systems, Ulster University)
Professor Joan Condell leads the Human Centred Computing team in Ulster University (Northern Ireland; NI) focusing on (big) data analytics, AI and IoT sensors for a range of applied research sectors. She manages a team of PhD researchers, Research Associates and Fellows across national, EU and commercial projects (led over 110 projects in her career). Professor Condell has published over 250 papers and actively secured grants from external sources with a total project value over £56M.
Professor Condell has considerable commercial experience; she is CEO of a spinout company ActionSense Ltd and exited a previous spinout company (HidInImage Ltd). She has numerous patents filed in the UK and the US, and has completed trials with key industrial players with a range of technologies. She has won Innovation and Enterprise awards for this commercialisation work for creativity and bio-entrepreneurship.
Professor Condell’s main focus is on adoption and implementation of medically aligned technologies into the health service. Joan set up the first NI community testbed, eCareWell, working with 20 local (NI) companies to test their technologies (hardware and software) with NI communities. She works very closely with early-stage companies and SMEs to test their product and/or service in terms of usability, function efficacy and acceptability by their target end-users. She also assists companies on software and hardware development and/or testing necessary for next-stage funding or investment. In asddition, she works alongside housing associations to look closely at the effect on health of net-zero targets and changes being implemented in NI and wider across the UK.
Professor Bibek Gooptu, Professor of Respiratory Biology, University of Leicester, Director of the Centre for Fibrosis Research, University of Leicester, Consultant in Respiratory Medicine, Glenfield/University Hospitals of Leicester (Job title at the start of the programme: Professor Bibek Gooptu, Professor of Respiratory Biology, University of Leicester)
Professor Bibek Gooptu’s research integrates studies of the molecular structures of proteins with cell and tissue studies and findings from clinical practice, to define and target mechanisms underlying chronic disease processes including inflammation, scarring and dementia.
He is a Consultant in Respiratory Medicine at Glenfield Hospital, a group leader within the NIHR Leicester Biomedical Research Centre, and Professor of Respiratory and Structural Biology at the University of Leicester (UoL) Institute of Structural & Chemical Biology (LISCB). He leads an initiative to expand UoL’s use of LISCB’s expertise and technical capabilities for Translational Medicine (SCBxTra).
He is the founding Director of the new interdisciplinary UoL Centre for Fibrosis Research (UoL CFR) and Chair of the East Midlands Interstitial Lung Disease (ILD) Research Alliance (EMIRA). Both UoL CFR and EMIRA integrate patient panels into scientific meetings to contribute to the development of new collaborative initiatives regionally and internationally.
Professor Gooptu dual-trained in biomedical research and medicine at The University of Manchester and the University of Cambridge (MB/PhD). As a junior doctor he undertook six years of full-time clinical work (East Anglia, Nottingham, London, Essex), before gaining further research experience with Structural Biology methods (crystallography, NMR, cryo-EM) at Birkbeck College and UCL (Wellcome Trust Intermediate Clinical Fellowship). He then worked as a Consultant and Senior Clinical Lecturer at Guy’s & St Thomas’ Hospitals/KCL prior to moving to Leicester.
Dr Gita Khalili Moghaddam, Principal Investigator, University of Cambridge
(Job title at the start of the programme: Dr Gita Khalili Moghaddam, UKRI Innovation Scholar, University of Cambridge)
Dr Gita is leading her mission to develop innovative diagnostics and AI solutions for early detection and precision therapeutics, aiming to improve patient outcomes by bridging academia, industry, entrepreneurship, and the NHS. Her international collaborations involve more than 10 countries and 20 entities, including those in the UK.
She is currently a Principal Investigator at the University of Cambridge (Department of Clinical Neurosciences) and a Royal Society Industry Fellow at GSK, focusing on innovative clinical trials to accelerate patient access to effective treatments. Previously, she was awarded a Borysiewicz Biomedical Sciences Fellowship at the University of Cambridge in recognition of her research in the field of bioengineering.
As a science-based entrepreneur, she has (co-)led four clinical trials to translate scientific ideas into working prototypes. Her efforts have been widely recognised, including being named an RAEng Engineers Trust Young Engineer of the Year in 2021. She innovated an imaging device for accurate cancer surgery in collaboration with Cambridge University Hospital. Additionally, she is leading a spin-off company to develop a continuous diagnostic monitoring wearable for metabolic health.
Dr Simon Lambden, Executive Medical Director, Translational and Experimental Medicine, Development, Regulatory and Safety, Alexion (AstraZeneca rare disease unit)
(Job title at the start of the programme: Dr Simon Lambden, Head of Medical Science, Inotrem)
Dr Simon Lambden is a clinician, scientist and executive with a focus on the development of novel therapies with the greatest unmet clinical needs.
A practising consultant in anaesthesiology and intensive care and, having completed his PhD and postdoctoral work in immunology, he developed a range of skills including therapeutic and companion diagnostic development, translational science and clinical development.
As a consultant, founder, executive or Chief Medical Officer in a number of biotechnology companies, he gained a broad exposure to the journey from discovery to late-stage clinical development. This includes the research, business development, regulatory and leadership activities that form a key part of a success in the biotech space.
Simon is currently leading translational and experimental medicine within the clinical development group at Alexion, AstraZeneca’s rare disease unit, with a focus on developing therapies for rare disease across a broad range of therapeutic areas using multiple treatment modalities. Other responsibilities include leadership in business development activities and building the relationship with the wider AstraZeneca organisation.
Professor Julie-Anne Little, Professor in Optometry & Vision Science, Ulster University
(Job title at the start of the programme: Dr Julie-Anne Little, Senior Lecturer in Optometry, Ulster University)
Julie-Anne Little is a Professor of Optometry and Vision Science at Ulster University. Her research focuses on investigating refractive error, accommodation and visual function in childhood, and aims to optimise vision, educational attainment and quality of life through effective eyecare interventions for individuals across the world.
Under her strategic leadership as Research Director for the Biomedical Sciences Research Institute at Ulster University, the multidisciplinary team of >100 researchers spanning nutrition, diabetes, genomic medicine, pharmaceutical and vision science was ranked world-leading in the UK Research Excellence Framework (REF) 2021: 5th in the UK for biomedical research, with a 100% world-leading research environment.
To date, she has authored 44 peer-reviewed journal articles with >1000 citations, with publications predominantly in Q1 Scimago-ranked journals in ophthalmology. Her outputs demonstrate her sustained focus on improving vision and eyecare for people with developmental disability, using cutting-edge methodologies coupled with clinical expertise in conducting optometric assessment of hard-to-test groups. They also reflect her research investigating the impact of uncorrected hyperopia in children for reading and near tasks, and epidemiological work on unmet visual need. Her research has been supported by grants from the Wellcome Trust, the Alzheimer’s Society, the EU (Horizon 2020, Marie Curie), NIHR, College of Optometrists, and various other sources.
She contributes to postgraduate and undergraduate optometry programmes and has a strong external profile in optometry as Chair of the European Council of Optometry and Optics Accreditation Agency, and as Chairman of the Association of Optometrists in the UK.
Emma Lowe, Transformation Director, NIHR Research Delivery Network
(Job title at the start of the programme: Emma Lowe, Head of Research Policy: Clinical Research and Growth, Department of Health and Social Care)
Emma works within the NIHR Research Delivery Network (RDN). Funded by the Department of Health and Social Care, the RDN supports the successful delivery of high-quality research across the health and care system. As Transformation Director, Emma is responsible for driving forward the implementation of the RDN future vision and the transformation of its services and functions.
Emma previously worked within the Science Research and Evidence Directorate at the Department of Health and Social Care, leading on policy related to clinical research and economic growth. In this role Emma co-authored ‘Saving and Improving Lives: the future of UK clinical research delivery’ and ‘The Full Government Response to the O’Shaughnessy Review’, led their implementation through the UK Clinical Research Recovery Resilience and Growth programme, and led Research Reset, a system-wide programme, which enabled the recovery of research in the NHS following the COVID-19 pandemic.
Emma has an MSc in People and Organisational Development from the Roffey Park Institute, and previously led the design and delivery of learning and workforce development programmes in the NIHR Clinical Research Network, including the NIHR’s Good Clinical Practice (GCP) programme.
Professor Charlotte Manisty, Professor of Cardiology, University College London
(Job title at the start of the programme: Dr Charlotte Manisty, Associate Professor of Cardiology, University College London)
Charlotte Manisty is a Professor of Cardiology and Head of Clinical Cardiovascular Research at University College London. She set up and leads the specialised cardio-oncology service at Barts Heart Centre. Her research group works on improving understanding of the cardiovascular toxic effects of cancer therapies, including developing imaging tools for better diagnosis and risk stratification.
She is also a co-founder and Echocardiography lead for MyCardium AI – a UCL spinout founded in April 2022 to transform how cardiovascular imaging is delivered in healthcare through the use of “super-human” AI. MyCardium AI delivers two AI-driven software solutions for analysis of MRI and echocardiography, alongside an imaging Core Lab facility supporting pharmaceutical and academic institutions conducting clinical trials.
Charlotte is the research lead for the British Cardio-Oncology Society and on the research council of the International Cardio-Oncology Society, alongside Board membership of the Society of Cardiovascular Magnetic Resonance. She also leads the UK Joint Working Group on MRI for patients with cardiac devices, which has brought together 13 national societies to deliver a four-fold increase in MRI provision, winning national awards for imaging. She is author of over 200 publications and her group have been awarded multiple national and international awards.
Dr Maeva May, Associate Director of Systems Engagement, Stroke Association
(Job title at the start of the programme: Dr Maeva May, Head of Policy, British Heart Foundation)
Dr Maëva May is a senior policy professional dedicated to enhancing the lives of patients, families, and healthcare providers through her work in research and health. Since September 2023, she has served as the Associate Director of Systems Engagement at the Stroke Association. In this role, Maëva oversees the research funding, policy and influencing, and systems partnerships teams, ensuring that research translates into tangible improvement in stroke care.
Prior to joining the Stroke Association, Maëva was the Head of Policy at the British Heart Foundation (BHF). There, she made significant contributions to national influencing efforts, particularly in research, primary prevention and healthcare. Notably, she collaborated with AMRC and CRUK on the Life Sciences Charity Partnership fund, which resulted in £115 million of Government support for early-career researchers over three years. Her team also produced pivotal reports on the COVID-19 pandemic’s impact on cardiovascular services, highlighting increased cardiology waiting lists and excess cardiovascular deaths.
In the United States, Maëva spent five years at the National Institutes of Health, the largest US biomedical research funder. She held strategic planning and evaluation roles at the National Cancer Institute and supported the Director of the National Heart, Lung, and Blood Institute, leading an initiative to boost women’s health research.
Initially trained as a veterinary internist, Maëva brings a unique combination of clinical, research, and policy and influencing experience to her roles, allowing her to draw on deep experience across sectors to achieve change, supported by her participation in the FLIER programme.
Dr Jacqueline Maybin, Reader, Centre for Reproductive Health, University of Edinburgh & Honorary Consultant Gynaecologist, NHS Lothian
(Job title at the start of the programme: Dr Jacqueline Maybin, Senior Clinical Research Fellow, MRC Centre for Reproductive Health, University of Edinburgh & Honorary Consultant Gynaecologist, NHS Lothian)
Dr Jackie Maybin leads a research programme that aims to develop better preventative and therapeutic strategies for abnormal uterine bleeding, a common and debilitating symptom. She has been awarded two Wellcome Fellowships (Postdoctoral & Clinical Career Development Fellowship) to investigate menstrual physiology and pathology with the aim of delineating the underpinning mechanisms of endometrial function to develop more effective, acceptable treatments for heavy menstrual bleeding. Her group has received national and international awards that recognise contributions to limiting health inequalities for those who menstruate.
Clinically, Jackie runs a specialist menstrual disorders service and offers medical treatments, as well as surgical interventions ranging from minimally invasive hysteroscopy and laparoscopy to open abdominal procedures.
Jackie was awarded her Medical Degree, BSc and PhD from the University of Edinburgh and completed her postdoctoral fellowship in KU Leuven, Belgium. She sits on the Editorial Board of Reproduction, the Journal of Endometriosis and Uterine Disorders and Physiological Reviews. Jackie is president of the Blair Bell Research Society, Chair of the Scottish Menstrual Health Clinical Forum and Deputy Chair of the Society for Endocrinology Corporate Liaison Committee. She is passionate about public and patient involvement in research, equality and diversity, and training the next generation of clinical and discovery scientists.
Dr Shivani Misra, Senior Clinical Lecturer in Diabetes, Imperial College London, Wellcome Trust Career Development Fellow and an Honorary Consultant in Metabolic Medicine at Imperial College Healthcare NHS Trust
(Job title at the start of the programme: Dr Shivani Misra, Senior Clinical Lecturer in Diabetes & Consultant in Metabolic Medicine, Imperial College London)
Dr Shivani Misra is a clinician scientist and leads a team of researchers who investigate early-onset type 2 diabetes heterogeneity. Funded through grants from the Wellcome Trust, Diabetes UK, and the Imperial Biomedical Research Council, her team has a broad focus on applying precision medicine tools to study diabetes heterogeneity with an emphasis on studying diverse ancestries, linking diabetes phenotype to outcomes and equitable healthcare.
Shivani is a recognised leader in the application of precision medicine for diabetes across diverse ancestries and resource settings. In 2023 she was awarded the Precision Medicine in Diabetes Prize from the Novo Nordisk Foundation and the European Association for the Study of Diabetes for related work.
In 2022 she clinically led the development of the Type 2 Diabetes in the Young (T2DAY) programme, which launched in 2023 and is backed by £14 million in funding from the NHS Diabetes programme. T2DAY aims to improve diabetes care delivery to adults living with early-onset type 2 diabetes, who have a reduced life expectancy.
Shivani is the Chair of the National Diabetes Audit group for young-onset type 2 diabetes at NHS Digital and internationally serves as Co-Chair for the NIDDK clinical working group on diabetes heterogeneity.
Dr Dhruv Parekh, Associate Professor in Critical Care and Respiratory Medicine, University of Birmingham
(Job title at the start of the programme: Dr Dhruv Parekh, Associate Professor in Critical Care and Respiratory Medicine, University of Birmingham)
As Director of the Birmingham NIHR/Wellcome Clinical Research Facility and Lead of the cross-cutting Acute Care Research Collaborative within the Birmingham Health Partnership, Dhruv oversees the delivery of a diverse portfolio of academic and industry-led research. His work involves engaging with the NHS, universities, funding and regulatory bodies, charities, and industry partners.
Dhruv is a Board member of the Faculty of Intensive Care Medicine, where he contributes to national clinical training and quality, workforce planning, and engages with clinical policy and governance stakeholders. His clinical training took place in London and Birmingham, during which he received prestigious awards including an MRC Clinical Research Training Fellowship, an NIHR Clinical Lectureship, and an NIHR CRN Career Development Fellowship.
With a comprehensive research programme, Dhruv spans the full spectrum of discovery science, from translation to phase two studies, to the design and delivery of large clinical and cost-effectiveness trials in acute, respiratory, and critical care.
Dhruv’s key areas of interest are:
1. Reducing health inequity, patient engagement and improving access to research studies
2. Enhancing the speed and translation of innovations to improve patient health outcomes
3. Tackling challenges in and improving clinical academic training
Passionate about reducing health disparities, Dhruv has a propensity towards building collaborations and a cross-sector approach to research. His leadership aims to make significant strides in ensuring that every patient, regardless of background, location, diversity, language, or disability, has equal access to healthcare advancements and research opportunities.
Professor Sheena Ramsay, Professor of Public Health & Epidemiology & Honorary Consultant in Public Health, Newcastle University
(Job title at the start of the programme: Dr Sheena Ramsay, Clinical Senior Lecturer & Honorary Consultant in Public Health, Newcastle University)
Sheena Ramsay is clinical academic in public health, and Director of Fuse: Centre for Translational Public Health Research. Fuse is a collaboration of the six North East universities, and public health practice and policy organisations.
Sheena leads a programme of research that aims to improve population health, with a particular focus on reducing health inequalities. Her research focuses on addressing socio-economic determinants of ill-health to improve the health and social care for the most disadvantaged populations. Sheena works closely with partners from local authorities, voluntary sector, policy, and healthcare. Central to her research is engaging with the public, particularly with under-represented populations (for example, deprived populations, older adults, homeless, substance users).
As a dental surgeon with specialisation in Public Health, she bridges epidemiology and public health research with policy and practice. She has held prestigious MRC Fellowships, undertaken Public Health Specialty Training in London, and been awarded grants from NIHR, UKRI, US NIH, and charities. Sheena plays an active role in training and building capacity in academic public health.
Dr Jenny Rivers, Director of Research & Development, Barts Health NHS Trust
(Job title at the start of the programme: Dr Jenny Rivers, Deputy Director of Research & Innovation, Great Ormond Street Hospital for Children NHS Foundation Trust)
Jenny joined Barts Health NHS Trust in October 2023 to develop and deliver the Trust’s research strategy. In this role, Jenny oversees the Trust’s research resources and infrastructure, including the Joint Research Management Office with Queen Mary University of London, the NIHR Barts Health Clinical Research Facility and hosts the Local Clinical Research Network, supporting clinical research delivery across the wider North Thames region.
This is Jenny's third NHS role; she was at Great Ormond Street Hospital for Children NHS Foundation Trust for five years, in the role of Acting Director of Research & Innovation for seven months, following her role as Associate Director of Research at the Royal Brompton & Harefield NHS Foundation Trust. Prior to these roles, Jenny worked in a variety of research management roles at the University of Liverpool, most recently Research and Impact Manager for the Faculty of Humanities & Social Sciences.
Jenny is an experienced research leader, having led large teams (c. 200 staff), driven research strategy across the NHS, academia and beyond, and managed operations, governance, and finance across complex and diverse research portfolios. Jenny has a BSc in Bioveterinary Science and a PhD in Biochemistry and has held postdoctoral academic positions in higher education and industry, including a collaborative Knowledge Transfer Partnership applying analytical proteomics to the dairy industry.
Professor Sarah Stock, Wellcome Leap In-Utero Program Director
(Job title at the start of the programme: Dr Sarah Stock, Reader & Honorary Consultant in Maternal and Fetal Medicine, University of Edinburgh)
Sarah Stock is a Professor in Maternal and Fetal Health and honorary consultant and subspecialist in Maternal and Fetal Medicine at the University of Edinburgh. She went to Manchester University Medical School and has a PhD from the University of Edinburgh.
Her training was undertaken in Edinburgh, with periods in Glasgow, London, and Australia. She has research interests in preterm birth and stillbirth. With a laboratory science background, she now focuses on clinical trials and international data-driven studies.
She is currently the 'In Utero' Programme Director at Wellcome Leap; a three-year, $50 million programme to reduce stillbirth rates by half, without increasing provider-initiated births.
Dr Helen Surana, Associate Editor, BMJ Innovations
(Job title at the start of the programme: Dr Helen Surana, Associate Editor, BMJ Innovations)
Helen Surana has had a varied career in medical publishing and digital education. She started as a junior doctor working in the NHS, specialising in anaesthetics, and then moved to the BMJ as clinical editor, via the Imperial Science Communication MSc programme and a role as health advisor in the House of Commons Library.
At BMJ she’s held leadership roles for multimedia, online learning, and digital content development, as well as leading on content for the events team.
She led a BMJ Learning project in Washington DC for 18 months to support the implementation of US health reforms and led the specialist engagement team at Macmillan Cancer Support. She’s launched the BMJ Research Forum, led the content team for the International Forum on Quality and Safety in Healthcare, and the launch of BMJ’s Future Health brand, which explores new ways to support the health research and innovation community to collaborate and communicate across events, scholarship, journalism, and podcasts. She holds consulting editorial roles with BMJ Open, BMJ Innovations and was interim Editor-in-Chief of BMJ Global Health.
Her professional passions are public engagement and inclusion in research and health, meaningful and effective digital development of healthcare services and cross-sector and interdisciplinary work. She enjoys developing and working with good advisory boards and speakers, and is a personable and confident chair, host and facilitator.
Professor Mike Trenell, Clinical Scientist in Health technologies and innovation
(Job title at the start of the programme: Professor Mike Trenell, Founder, Changing Health & Honorary Professor of Digital Medicine, Newcastle University)
Working across the life science sector (academia, policy, industry), he has published >130 peer-reviewed papers and also directed teams who built the national horizon-scanning platform (Department of Health and Social Care) and national education programme for type 2 diabetes (NHS England).
That means that today, any medicine approved for use in the UK will have used intelligence gathered by a team Mike established. Every patient living with type 2 diabetes in the UK has access to evidence-based education, for free, on platforms that were built by Mike’s team.
He is passionate about helping the next generation of leaders and is an active mentor for UKRI (in technology and AI), Chair of the UKRI Doctoral Training Centre for Digital Health and is a past expert advisor for UKRI and NICE on technology and health.
In his work with the Academy of Medical Sciences, Mike is focused on helping understand how to help people build and use digital technologies, creating DAISER, a platform that helps anyone, anywhere get access to digital health technologies.
Professor Paul Welsh, Professor of Molecular Epidemiology, University of Glasgow
(Job title at the start of the programme: Dr Paul Welsh, Reader, Institute of Cardiovascular and Medical Sciences, University of Glasgow)
Paul is an epidemiologist with a wide range of research interests encompassing biomarkers, lifestyle, and clinical research in the fields of cardiovascular disease, diabetes, metabolism, and healthy ageing, including influential clinical trials, large observational studies and meta-analyses. His eclectic portfolio of work includes >300 publications with an H-index of >65. Recently, he led the revision of the Scottish national cardiovascular risk score, ASSIGN 2, which is now being integrated into clinical practice.
Paul founded and leads the Glasgow Biomarker Research Unit (GlasBRU) at the University of Glasgow. GlasBRU was developed to drive a cross-sector collaboration between the University of Glasgow, Roche Diagnostics and NHS Greater Glasgow and Clyde, culminating in the funding of the Glasgow Biomarker Centre of Clinical Excellence in Heart Failure. This innovative long-term partnership aims to identify and address the unmet needs of heart failure patients in optimising the care pathway. His group also collaborates extensively with AstraZeneca, Novartis, Boehringer Ingelheim and other industrial partners.